Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 369-374

  Miki, Ikuya ^a   Tamura, Takao ^a   Nakamura, Tsutomu ^b   Makimoto, Hiroo ^b   Hamana, Noriko ^b   Uchiyama, Hitoshi ^b   Shirasaka, Daisuke ^a   Morita, Yoshinori ^a   Yamada, Hiroyuki ^a   Aoyama, Nobuo ^b   Sakaeda, Toshiyuki ^b   Okumura, Katsuhiko ^b   Kasuga, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Circadian variation; CLOCK; Esophageal cancer

Indexed keywords

CISPLATIN; CYTOSINE; FLUOROURACIL; THYMINE; TRANSCRIPTION FACTOR CLOCK;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLOCK GENE; COEFFICIENT OF VARIATION; DRUG BLOOD LEVEL; DRUG INFUSION; ESOPHAGUS CARCINOMA; GENE; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VARIANCE; WILCOXON SIGNED RANKS TEST;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CIRCADIAN RHYTHM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TRANS-ACTIVATORS;

EID: 20044362013     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000162554.23501.e6     Document Type: Article

References (39)

1. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004;22:1743-1752.
2. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol. 2003;14(Suppl 2):ii49-ii55.
3. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any)M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425-433.
4. Shore S, Raraty MG, Ghaneh P, et al. Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther. 2003;18:1049-1069.
5. Nguyen HN, Nordqvist SR. Chemotherapy of advanced and recurrent cervical carcinoma. Semin Surg Oncol. 1999;16:247-250.
6. Drewinko B, Yang LY. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep. 1985;69:1391-1398.
7. Calabro-Jones PM, Byfield JE, Ward JF, et al. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res. 1982;42:4413-420.
8. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301-308.
9. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537-3541.
10. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol. 1996;14:3156-3174.
11. Kallman RF. The importance of schedule and drug dose intensity in combinations of modalities. Int J Radiat Oncol Biol Phys. 1994;28:761-771.
12. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915-2921.
13. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88:18-24.
14. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623-1627.
15. Gaspar LE, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer. 2000;88:988-995.
16. Denham JW, Ackland SP, Burmeister B, et al. Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy. Eur J Cancer. 1999;35:921-927.
17. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167-1174.
18. Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50:197-201.
19. Petit E, Milano G, Levi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988;48:1676-1679.
20. Erlichman C, Fine S, Elhakim T. Plasma phamiacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep. 1986;70:903-904.
21. Thyss A, Milano G, Renee N, et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol. 1986;16:64-66.
22. Piggins HD. Human clock genes. Ann Med. 2002;34:394-400.
23. Katzenberg D, Young T, Finn L, et al. A CLOCK polymorphism associated with human diurnal preference. Sleep. 1998;21:569-576.
24. Sawai Y, Yamaoka K, Ito T, et al. Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. Biol Pharm Bull. 1997;20:1313-1316.
25. Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res. 2002;19:1581-1585.
26. Desan PH, Oren DA, Malison R, et al. Genetic polymorphism at the CLOCK gene locus and major depression. Am J Med Genet. 2000;96:418-421.
27. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 1989;59:287-290.
28. Vokes EE, Mick R, Kies MS, et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996;14:1663-1671.
29. Bensadoun RJ, Etienne MC, Dassonville O, et al. Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. Int J Radiat Oncol Biol Phys. 1998;42:237-245.
30. Takimoto CH, Yee LK, Venzon DJ, et al. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res. 1999;5:1347-1352.
31. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-2206.
32. Metzger G, Massari C, Etienne MC, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther. 1994;56:190-201.
33. McDermott BJ, van den Berg HW, Murphy RF. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol. 1982;9:173-178.
34. Deleted in proof.
35. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer. 1998;34:92-97.
36. Milano G, Etienne MC. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit. 1996;18:335-340.
37. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998;4:2039-2045.
38. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int. 2002;19:177-189.
39. Grem JL, Yee LK, Venzon DJ, et al. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol. 1997;40:117-125.